The heavy disease burden is mainly due to diabetic complications. Diabetes is a major risk factor for cardiovascular disease (CVD) and chronic kidney disease (CKD).China has been the largest absolute disease burden of diabetes in the world recently1. Diabetic patients with established CVD or CKD are bringing growing pressure upon our nation's healthcare expenditure1. However, the characteristic profile of Chinese diabetic patients who has CVD, CKD or at high risk of CVD remains unclear thus is in urgent need for in-depth investigation.In current China, however, the information regarding diabetes or non-diabetes patients who also had other comorbid conditions (e.g. established CV diseases, CKD or at high risk for such problem), is limited; the patient characteristics, treatment patterns and economic burden may not be fully understood.Therefore, based on TianJin regional database, the investigators will describe the demographic, clinical characteristics, treatment, and economic burden of disease of Chinese diabetic/non-diabetic patients with/without established CV disease, CKD, or at high CV risk including hypertension and hyperlipidaemia. And the investigators believe that the resulting findings will inform a comprehensive group of evidence users to achieve better healthcare for diabetes patients with established or at high risk of CVD or CKD.
The study aimed to investigate the clinical characteristics, treatment, and economic burden of disease of Chinese diabetic/non-diabetic patients with/without established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk, including: 1. estimate the proportion of Chinese diabetic/non-diabetic patients with established cardiovascular disease, CKD, or at high cardiovascular risk including hypertension and hyperlipidaemia; 2. describe the demographic and clinical characteristics of Chinese diabetic/non-diabetic patients with/without established cardiovascular disease, CKD, or at high cardiovascular risk; 3. investigate the treatment patterns of Chinese diabetic/non-diabetic patients with/without established cardiovascular disease, CKD, or at high cardiovascular risk; 4. examine economic burden of disease of Chinese diabetic/non-diabetic patients with/without established cardiovascular disease, CKD, or at high cardiovascular risk; 5. explore the trends of clinical characteristics, treatment pattern, economic burden of inpatients over time (2008, 2013, and 2018 separately);
Study Type
OBSERVATIONAL
Enrollment
200,000
Tian Jin Healthcare Big Data Co. Ltd
Tianjin, Tianjin Municipality, China
The number of diabetic/non-diabetic patients with disease or risk
The number of diabetic patients with established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk among all patients with diabetes;
Time frame: 10 months after enrollment
The proportion of diabetic/non-diabetic patients with disease or risk
The proportion of diabetic/non-diabetic patients with established cardiovascular disease, chronic kidney disease, or at high cardiovascular risk among patients without diabetes
Time frame: 10 months after enrollment
The demographic characteristics of the last visit for all patients of the studied population
1. age at admission; 2. gender; 3. ethnic; 4. insurance payment;
Time frame: 10 months after enrollment
The diagnosis of patients
The number of patients with diagnosis at the last visit
Time frame: 10 months after enrollment
The proportion of death
The proportion of death at the last visit; the proportion of death at admission of the last visit for inpatients in 2008, 2013 and 2018.
Time frame: 10 months after enrollment
Random blood glucose (mmol/L)
The most recent value of random blood glucose (mmol/L) within the previous year for outpatients; the value of random blood glucose (mmol/L) at admission of the last visit for inpatients in 2008, 2013, 2018.
Time frame: 12 months after enrollment
HbA1C (%)
The most recent value of HbA1C (%) within the previous year for outpatients; the value of HbA1C (%) at admission of the last visit for inpatients in 2008, 2013, 2018.
Time frame: 12 months after enrollment
Department of discharge for hospitalized patients
Department of discharge of the last visit for hospitalized patients; and summarize the number of patients of different department of discharge in 2008, 2013, 2018.
Time frame: 12 months after enrollment
serum creatinine (μmol/L)
The most recent value of serum creatinine (μmol/L) within the previous year for outpatients; the value of serum creatinine (μmol/L) at admission of the last visit for inpatients in 2008, 2013, 2018.
Time frame: 12 months after enrollment
eGFR (mL/min/1.73m2)
The most recent value of eGFR (mL/min/1.73m2) within the previous year for outpatients; the value of eGFR (mL/min/1.73m2) at admission of the last visit for inpatients in 2008, 2013, 2018.
Time frame: 12 months after enrollment
Microalbuminuria (MALB) (mg/24h)
The most recent value of microalbuminuria (MALB, mg/24h) within the previous year for outpatients; the value of microalbuminuria (MALB, mg/24h) at admission of the last visit for inpatients in 2008, 2013, 2018.
Time frame: 12 months after enrollment
High density lipoprotein (HDL) (mmol/L)
The lasted examination of high density lipoprotein (HDL) (mmol/L) within the last year for outpatients; the value of high density lipoprotein (HDL) (mmol/L) at admission of the last visit for inpatients in 2008, 2013, 2018.
Time frame: 12 months after enrollment
Low density lipoprotein (LDL) (mmol/L)
The lasted examination of low density lipoprotein (HDL) (mmol/L) within the last year for outpatients; the value of low density lipoprotein (HDL) (mmol/L) at admission of the last visit for inpatients in 2008, 2013, 2018.
Time frame: 12 months after enrollment
Total cholesterol (TC) (mmol/L)
The lasted examination of total cholesterol (TC) (mmol/L) within the last year for outpatients; the value of total cholesterol (TC) (mmol/L) at admission of the last visit for inpatients in 2008, 2013, 2018.
Time frame: 12 months after enrollment
Triglyceride (TG) (mmol/L)
The lasted examination of triglyceride (TG) (mmol/L) within the last year for outpatients; the value of triglyceride (TG) (mmol/L) at admission of the last visit for inpatients in 2008, 2013, 2018.
Time frame: 12 months after enrollment
The number of patients with different treatment pattern
1. number of patients with the treatment of antiplatelet drug,statin,vasodilators. 2. number of patients with the treatment of different insulin and OHA prescription; 3. number of patients with the treatment of anti-hypertensive drugs (CCB, ACEI/ARB, beta-blocker and diuretic) 4. number of patients with the treatment of statin and fibrates; 5. number of patients with the treatment of the dialysis, ACEI/ARB and the kindney transplantation. We descirbe the treatment pattern based on treatment prescribed during the most recent visit for all inpatients, and based on at least 2 prescription within the previous year for outpatients
Time frame: 10 months after enrollment
The length of stay in the hospital
describe the length of stay in the hospital of the last hospitalization, the length stay in the hospital for inpatients from 2008 to 2018.
Time frame: 12 months after enrollment
The economic burden
hospitalization cost of the studied population for the last visit; total cost and hospitalization cost of the studied population from 2008 to 2018.
Time frame: 12 months after enrollment
Numbers of admissions
The total number of admissions for inpatients from 2008 to 2018
Time frame: 12 months after enrollment
The proportion of re-hospitalization
The last visiting and previous one within 30 days and 90 days
Time frame: 12 months after enrollment
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.